Tony de Fougerolles

Summary

Affiliation: Alnylam Pharmaceuticals
Country: USA

Publications

  1. ncbi Interfering with disease: a progress report on siRNA-based therapeutics
    Antonin de Fougerolles
    Alnylam Pharmaceuticals Inc, 300 Third Street, Cambridge, Massachusetts 02142, USA
    Nat Rev Drug Discov 6:443-53. 2007
  2. doi Delivery vehicles for small interfering RNA in vivo
    Antonin R de Fougerolles
    Alnylam Pharmaceuticals, Cambridge, MA 02142, USA
    Hum Gene Ther 19:125-32. 2008
  3. pmc A status report on RNAi therapeutics
    Akshay K Vaishnaw
    Alnylam Pharmaceuticals Inc, 300 Third Street, Cambridge, MA 02142, USA
    Silence 1:14. 2010
  4. doi siRNA and the lung: research tool or therapeutic drug?
    Antonin de Fougerolles
    Alnylam Pharmaceuticals, 300 Third Street, Cambridge, MA 02142, United States
    Curr Opin Pharmacol 8:280-5. 2008
  5. pmc Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death
    Vineet Bhandari
    Division of Perinatal Medicine, Yale University School of Medicine, Department of Pediatrics, 333 Cedar Street, New Haven, Connecticut 06520 8064, USA
    Nat Med 12:1286-93. 2006

Collaborators

  • Hans Peter Vornlocher
  • J Lieberman
  • Antonin de Fougerolles
  • Antonin R de Fougerolles
  • Akshay K Vaishnaw
  • John Maraganore
  • Vineet Bhandari
  • Jared Gollob
  • Christina Gamba-Vitalo
  • Rachel Meyers
  • Dinah Sah
  • Renta Hutabarat
  • Tatiana Novobrantseva
  • Patty J Lee
  • Xucher Zhang
  • Rayman Choo-Wing
  • Anke Geick
  • Geoffrey L Chupp
  • Jonathan H Nedrelow
  • Chun G Lee
  • Robert J Homer
  • Lorraine B Ware
  • Zhou Zhu
  • Jack A Elias
  • Michael A Matthay

Detail Information

Publications5

  1. ncbi Interfering with disease: a progress report on siRNA-based therapeutics
    Antonin de Fougerolles
    Alnylam Pharmaceuticals Inc, 300 Third Street, Cambridge, Massachusetts 02142, USA
    Nat Rev Drug Discov 6:443-53. 2007
    ..We conclude by reviewing the latest clinical experience with RNAi therapeutics...
  2. doi Delivery vehicles for small interfering RNA in vivo
    Antonin R de Fougerolles
    Alnylam Pharmaceuticals, Cambridge, MA 02142, USA
    Hum Gene Ther 19:125-32. 2008
    ..Lastly, a status report on current clinical trials using siRNA is given...
  3. pmc A status report on RNAi therapeutics
    Akshay K Vaishnaw
    Alnylam Pharmaceuticals Inc, 300 Third Street, Cambridge, MA 02142, USA
    Silence 1:14. 2010
    ....
  4. doi siRNA and the lung: research tool or therapeutic drug?
    Antonin de Fougerolles
    Alnylam Pharmaceuticals, 300 Third Street, Cambridge, MA 02142, United States
    Curr Opin Pharmacol 8:280-5. 2008
    ..In this review, we will discuss the progress made in developing RNAi therapeutics for the treatment of respiratory diseases...
  5. pmc Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death
    Vineet Bhandari
    Division of Perinatal Medicine, Yale University School of Medicine, Department of Pediatrics, 333 Cedar Street, New Haven, Connecticut 06520 8064, USA
    Nat Med 12:1286-93. 2006
    ..Tracheal Ang2 is also increased in neonates that develop bronchopulmonary dysplasia. Ang2 is thus a mediator of epithelial necrosis with an important role in hyperoxic ALI and pulmonary edema...